Obstructive Clinical Trials

671 recruitingLast updated: June 18, 2026

There are 671 actively recruiting obstructive clinical trials across 68 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4, Early Phase 1. Top locations include Beijing, Beijing Municipality, China, Philadelphia, Pennsylvania, United States, London, United Kingdom. Updated daily from ClinicalTrials.gov.


Obstructive Trials at a Glance

671 actively recruiting trials for obstructive are listed on ClinicalTrialsFinder across 6 cities in 68 countries. The largest study group is Not Applicable with 270 trials, with the heaviest enrollment activity in Beijing, Philadelphia, and London. Lead sponsors running obstructive studies include AstraZeneca, China-Japan Friendship Hospital, and VA Office of Research and Development.

Browse obstructive trials by phase

Treatments under study

About Obstructive Clinical Trials

Looking for clinical trials for Obstructive? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Obstructive trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Obstructive clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 671 trials

Recruiting
Not Applicable

Mindful-Breath for People With COPD

MindfulnessChronic Obstructive Pulmonary Disease (COPD)Pulmonary Rehabilitation
The University of Hong Kong60 enrolled1 locationNCT07195838
Recruiting

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

Pulmonary Disease, Chronic Obstructive
AstraZeneca2,000 enrolled7 locationsNCT06712563
Recruiting
Not Applicable

Treatment Failure of Continuous Positive Airway Pressure (CPAP) in Patients With Obstructive Sleep Apnea Syndrome (OSA): A Trial Comparing Polysomnography and the Sunrise Device to Drive Treatment-Adjustment Decisions.

Sleep Apnea Syndrome, Obstructive
University Hospital, Grenoble105 enrolled1 locationNCT07530302
Recruiting

Study of Microbiological Diversity in Exhaled Air in COPD and Free of COPD

Chronic Obstructive Pulmonary Disease
Centre Hospitalier Intercommunal Creteil240 enrolled1 locationNCT05437198
Recruiting
Phase 2Phase 3

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

Moderate to Severe Chronic Obstructive Pulmonary Disease
Pfizer1,156 enrolled87 locationsNCT07363694
Recruiting
Not Applicable

Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation

Sleep-disordered breathing (SDB)Obstructive Sleep ApneaArrhythmia+3 more
Beijing Anzhen Hospital658 enrolled27 locationsNCT07444372
Recruiting

Innate Immunity in COPD

Chronic Obstructive Pulmonary Disease
University of Edinburgh189 enrolled2 locationsNCT05743582
Recruiting
Phase 3

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled215 locationsNCT07190209
Recruiting
Phase 3

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled213 locationsNCT07190222
Recruiting

Development of a Wearable Point of Care Monitoring Device for Pediatric Obstructive Sleep Apnea

Pediatric Obstructive Sleep Apnea
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)120 enrolled1 locationNCT05052216
Recruiting

Study That Will Evaluate the Brazilian Population With COPD.

COPD, Chronic Obstructive Pulmonary Disease
AstraZeneca693 enrolled10 locationsNCT06780046
Recruiting

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb1,700 enrolled99 locationsNCT05489705
Recruiting
Not Applicable

Atrial Fibrosis in Obstructive Sleep Apnea Patients: A Pilot Study

Atrial FibrillationObstructive Sleep Apnea
Tulane University60 enrolled3 locationsNCT04814420
Recruiting
Phase 4

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease
Sanofi218 enrolled68 locationsNCT07053423
Recruiting

Breathlessness Perceptions Within Respiratory Diseases

Chronic Obstructive Pulmonary Disease (COPD)BronchiectasisAsthma (Diagnosis)+2 more
University Hospitals, Leicester75 enrolled1 locationNCT07648082
Recruiting
Phase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep Apnea
Amgen250 enrolled54 locationsNCT07226765
Recruiting

Measurements Before and After Participation in a Health Intervention Programme in Halsnaes Municipality

Chronic Obstructive Pulmonary Disease (COPD)Cardiovascular DiseaseType 2 Diabetes
Steno Diabetes Center Copenhagen194 enrolled1 locationNCT07641309
Recruiting
Phase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

ObesityObstructive Sleep Apnea
Amgen250 enrolled60 locationsNCT07225686
Recruiting
Phase 3

Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations

Chronic Obstructive Pulmonary DiseaseCOPD
AstraZeneca82 enrolled13 locationsNCT07566195
Recruiting

Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics

Respiratory (Chronic Obstructive Pulmonary Disease)
AstraZeneca1,000 enrolled2 locationsNCT07315958